JAK Inhibitor Halts the Progression of Acute Exacerbation of Alopecia Areata
July 2025
in “
Journal of Investigative Dermatology
”
This study evaluated the efficacy of baricitinib, a JAK inhibitor, in treating acute alopecia areata (AA) in patients with over 30% scalp involvement. The retrospective review found that baricitinib reduced hair shedding within 2 to 15 weeks and completely halted it by 12 weeks, with hair regrowth observed at an average of 11 weeks. By six months, no patients had a Severity of Alopecia Tool (SALT) score greater than 20. While the study suggests that early intervention with baricitinib may alter the disease course by rapidly stopping hair shedding and promoting regrowth, the small sample size and short follow-up period highlight the need for further research to confirm these findings and explore the broader efficacy of JAK inhibitors in managing acute AA.